Affordable Access

Access to the full text

Phase 1/2 Study of Synchronous Methotrexate, Cisplatin, Vincristine (MOPq10) Chemotherapy and Radiation for Patients with Locally Advanced Bladder Cancer

Authors
  • Goonewardene, T.I.
  • Bozcuk, H.
  • Oliver, R.T.D.
  • Barua, J.
  • Nargund, V.
  • Philip, T.
  • Mair, G.
  • Gibbs, S.
Type
Published Article
Journal
Urologia Internationalis
Publisher
S. Karger AG
Publication Date
Nov 01, 2001
Volume
67
Issue
4
Pages
293–297
Identifiers
DOI: 10.1159/000051006
Source
Karger
Keywords
License
Green
External links

Abstract

Purpose: This phase 1/2 study was designed to test toxicity and effectiveness of combination chemotherapy and concurrent radiotherapy in the treatment of invasive bladder cancer. Methods and Materials: 17 patients with localised muscle-invasive bladder cancer, clinical stages T2–3 N0, M0, were treated with a radiotherapy schedule of 55 Gy in 20 fractions over 4 weeks restricted to the bladder and 3 cycles of concurrent dose-intensive combination chemotherapy consisting of cisplatin 60 mg/m2, vincristine 2 mg and methotrexate 60 mg/m2 at 10-day intervals (MOPq10). Results: The complete remission rate following MOPq10 chemotherapy and radiotherapy was 88% as assessed at first cystoscopy with 82% remaining disease-free at 1 year. Risk factor analysis shows those older than 63 years (median) and those with creatinine clearance equal or less than the mean did worse. Actuarial disease-free survival at 2 years was 68% and of the patients treated 4/17 experienced acute G3/4 toxicity. Conclusion: This combination regimen was feasible. Its high initial response rate justifies further exploration in a randomised phase 2/3 trial setting with bladder volume and quality of life assessment.

Report this publication

Statistics

Seen <100 times